Episode Summary

Angeli Moeller is a molecular biologist, a neuroscientist, a systems biologist, and a data scientist all rolled into one—which makes her a perfect example of the kind of multidisciplinary executive needed for this new digital health ecosystem defined by big data, AI, and machine learning. She's a founding member of the Alliance for Artificial Intelligence in Healthcare, does extensive work for the nonprofit rare disease advocacy group Rare-X, and has spent almost five years managing global data assets and IT partnerships at Bayer. At the beginning of 2021 she became the head of international pharma informatics for Roche, the world’s largest drug company. Harry caught up with her on Zoom in February, and the conversation started with the role of informatics at Roche, but quickly expanded to cover all the areas where deep learning and other forms of AI and data science are transforming drug discovery and healthcare, and what life sciences entrepreneurs need to do to get on board.


The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.